NewLimit raises $435M Series C to take its liver reprogramming medicine toward human trials

NewLimit/Hepatocyte epigenetic reprogramming

NewLimit closed a $435 million Series C led by Founders Fund. The company says the round brings its first aging reprogramming medicine, a liver therapy, to human clinical trials next year.

• $435M Series C led by Founders Fund; new investors include Thrive Capital, Greenoaks and Quiet Capital; returning investors include Kleiner Perkins and Eli Lilly Ventures.
• The company had earlier expected trials to take more than a decade; it now cites an accelerated timeline based on a prototype that reverses cell age in old human liver cells.
• The therapy is an mRNA payload delivered in lipid nanoparticles, aimed at helping livers heal faster after injury.
• The company has not announced manufacturing milestones in this post.